Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
ChemMedChem2017Vol. 12(21), pp. 1776–1793
Citations Over TimeTop 1% of 2017 papers
Ulrich Lücking, Arne Scholz, Philip Lienau, Gerhard Siemeister, Dirk Kosemund, Rolf Bohlmann, Hans Briem, Ildiko Terebesi, Kirstin Meyer, Katja Prelle, Karsten Denner, Ulf Bömer, Martina Schäfer, Knut Eis, Ray Valencia, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Karl Ziegelbauer, Bert Klebl, Axel Choidas, Peter Nußbaumer, Matthias Baumann, Carsten Schultz‐Fademrecht, Gerd Rühter, Jan Eickhoff, Michael Brands
Abstract
Selective inhibition of exclusively transcription-regulating PTEFb/CDK9 is a promising new approach in cancer therapy. Starting from lead compound BAY-958, lead optimization efforts strictly focusing on kinase selectivity, physicochemical and DMPK properties finally led to the identification of the orally available clinical candidate atuveciclib (BAY 1143572). Structurally characterized by an unusual benzyl sulfoximine group, BAY 1143572 exhibited the best overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats. BAY 1143572 is the first potent and highly selective PTEFb/CDK9 inhibitor to enter clinical trials for the treatment of cancer.
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited
- Characteristics of Marine Environment in Coastal Waters for Stationary Fisheries.- Physical and Chemical Environments(2006)
- → Sedimentation rates in Kagoshima Bay, Southwestern Japan, using the210Pb method(2012)
- Final report for EL 22744 Arrla Bay 1, EL 22708 Arrla Bay 2, EL 24657 Arrla Bay 2a, EL 23972 Arrla Bay 5, EL 27156 Arrla Bay 5a, EL 27157 Arrla Bay 5b and EL 24108 Arrla Bay 6(2011)